In this study directed by Uribe-Herranz et al., mice receiving vancomycin in combination with murine CD19bbz CAR-T-cell therapy showed an increased tumor response and tumor-associated antigen (TAA) cross-presentation compared with those of mice receiving CD19 CAR-T-cell therapy alone, both in lymphoma and melanoma murine models. Here, CD19 is linked to lymphoma.